Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case–control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC)

Daniel E. Clark1,3*, Jeffrey M. Dendy1, Dan L. Li1, Kimberly Crum2, Debra Dixon1, Kristen George-Durrett2, Amar P. Parikh1, Jean W. Wassenaar1, Sean G. Hughes1† and Jonathan H. Soslow2†

Abstract

Background: Myocarditis is a potential complication after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and a known cause of sudden cardiac death. Given the athletic demands of soldiers, identification of myocarditis and characterization of post-acute sequelae of SARS-CoV-2 infection with cardiovascular symptoms (CV PASC) may be critical to guide return-to-service. This study sought to evaluate the spectrum of cardiac involvement among soldiers with cardiopulmonary symptoms in the late convalescent phase of recovery from SARS-CoV-2 compared to a healthy soldier control group, and to determine the rate of progression to CV PASC.

Methods: All soldiers referred for cardiovascular magnetic resonance (CMR) imaging for cardiopulmonary symptoms following COVID-19 were enrolled and matched by age, gender, and athletic phenotype 1:1 to soldiers undergoing CMR in the year prior to the first case of COVID-19 at our institution. Demographic, clinical, laboratory, and imaging parameters were compared between groups. The diagnosis of acute myocarditis was made using modified Lake Louise criteria. Wilcoxon rank sum and chi-squared tests were used for comparison of continuous and categorical variables, respectively.

Results: Fifty soldier cases and 50 healthy soldier controls were included. The median time from SARS-CoV-2 detection to CMR was 71 days. The majority of cases experienced moderate symptoms (N = 43, 86%), while only 10% required hospitalization. The right ventricular (RV) ejection fraction (RVEF) was reduced in soldier cases compared to controls (51.0% vs. 53.2%, p = 0.012). Four cases were diagnosed with myocarditis (8%), 1 (2%) was diagnosed with Takotsubo cardiomyopathy, and 1 (2%) had new biventricular systolic dysfunction of unclear etiology. Isolated inferior RV septal insertion late gadolinium enhancement (LGE) was present in 8 cases and 8 controls (16% vs. 24%, p = 0.09).

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Seven of the 19 (37%) cases that completed an intermediate-term follow-up survey reported CV PASC at a median of 139 days of follow-up. Two of the 7 soldiers (29%) with CV PASC had a pathological clinical diagnosis (myocarditis) on CMR.

Conclusions: Cardiovascular pathology was diagnosed in 6 symptomatic soldiers (12%) after recovery from SARS-CoV-2, with myocarditis found in 4 (8%). RVEF was reduced in soldier cases compared to controls. CV PASC occurred in over one-third of soldiers surveyed, but did not occur in any soldiers with asymptomatic acute SARS-CoV-2 infection.

Keywords: COVID-19, Myocarditis, Athletes, Soldiers, Return-to-service, Sports Cardiology

Background
Myocarditis is a leading cause of sudden cardiac death (SCD) among athletes and has been identified on autopsy in up to 20% of military recruits after SCD [1]. Cardiovascular sequelae of coronavirus disease 2019 (COVID-19) include myocardial inflammation and edema [2], and an initial case series of competitive collegiate athletes found a high prevalence of myocardial late gadolinium enhancement (LGE) and myocarditis using cardiovascular magnetic resonance (CMR) [3]. More recent cohorts of universally screened collegiate athletes suggested a low prevalence of myocarditis among these minimally symptomatic athletes (1–3%) [4, 5]. The American College of Cardiology (ACC) Sports Cardiology expert panel proposed return-to-play recommendations for competitive and master athletes, with CMR reserved for those with abnormal initial screening or ongoing cardiovascular symptoms [6]. However, there are no data on the prevalence of myocardial pathology related to COVID-19 in soldiers, nor are there any expert recommendations to guide return-to-service. Soldiers represent a unique athletic population, as the physical rigor of their training combines strength and endurance activities mixed with external stressors: environmental (ambient temperatures), mental (fatigue, sleep deficits), and emotional (injuries, casualties, and separation from friends and family for prolonged time periods). We hypothesized that soldiers who recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (cases) and experienced ongoing cardiopulmonary symptoms in late convalescence would have an increased prevalence of cardiovascular pathology by CMR evaluation compared to an age- and sex-matched soldier control group (controls). We additionally surveyed soldier cases for characterization of post-acute sequelae of SARS-CoV-2 infection with cardiovascular symptoms (CV PASC).

Methods
Study design and patient population
Soldier cases with ongoing cardiac symptoms were clinically referred for physical examination, electrocardiography (ECG), and a contrast CMR exam with parametric mapping. Healthy soldier controls were retrospectively identified from adult subjects who had clinically performed CMR exams at our institution in the 12 months (March 2019–February 2020) preceding our region’s first case of COVID-19. Soldier controls were only included if they were found to have normal cardiac function without myocardial pathology. Soldier cases and controls were included if active duty or recent military retirement in the prior year. All soldiers routinely exceed 6 hours of strenuous activity per week, with active duty soldiers performing over 14 hours weekly in activities that include endurance (marches, runs) and strength training (obstacle courses, moving heavy equipment). Failure to meet or exceed physical training standards, including a minimum score on the various physical training events and/or failure to meet height and weight standards are grounds for separation from the military. The elite (special operative) units perform much higher levels of physical exertion as a regular part of their daily training regimen.

Punctate inferior right ventricular (RV) septal insertion LGE was not considered a pathologic exclusion criterion, as this is common among healthy athletes [4, 7]. Controls were matched by age-, gender-, and athletic phenotype to cases in a 1:1 manner. Clinical demographics, laboratory, ECG, and CMR results were stored in the REDCap electronic platform [8]. COVID-19 severity was classified according to the ACC Sports Cardiology expert consensus recommendations [6]. Mild symptoms were defined as any combination of the following: anosmia, ageusia, headache, mild fatigue, mild upper respiratory tract illness, and mild gastrointestinal illness. Moderate symptoms were defined as fever, chills, myalgias, lethargy, dyspnea, and chest tightness. Severe symptoms were defined as those requiring COVID-19-related hospitalization [6].

Our laboratory’s normal values for parametric mapping were derived from a cohort of 54 healthy controls of varying age (range 7–56 years old) and gender (N = 29 male) prospectively enrolled and then segregated into the appropriate gender and age (>18 years and <18 years) category for comparison. Normal ranges were defined as the mean ±2 standard deviations. A left ventricular (LV) ejection fraction (LVEF) of 50–55% was considered normal in this cohort of competitive athletes [7, 9].
CMR protocol
A comprehensive CMR with contrast was performed on a 1.5 T CMR system (Avanto Fit, Siemens Healthineers, Erlangen, Germany). The CMR protocol consisted of cine CMR balanced steady-state free precession (bSSFP) imaging to calculate LV and RV volumes, LVEF, and LV mass. Intravenous gadolinium contrast (gadobutrol, Gadavist®, Bayer Healthcare Berlin, Germany) at a dose of 0.15 mmol/kg was administered through a peripheral intravenous line. LGE was performed using segmented inversion recovery (optimized inversion time to null myocardium) and single shot phase sensitive inversion recovery (inversion time of 300 ms) imaging in standard long-axis planes and a short-axis stack.

Native T1 mapping, T2 mapping, and post-contrast (15 min after contrast administration) T1 mapping was performed at the base and mid-LV in the short axis stack. All parametric mapping sequences were breath-held; any image felt to be inadequate due to poor breath holds or poor motion correction was repeated at the time of the scan. T1 mapping was performed using a sequence acquired using a 5(3s)/3 protocol before contrast and 4(13s)/12 protocol after contrast. Modified Look-Locker inversion recovery (MOLLI) sequences were motion-corrected, ECG-triggered images obtained in diastole with typical imaging parameters: non-selective inversion with a 35 degree flip angle, single shot bSSFP imaging, initial inversion time of 120 ms with 80 ms increments, field of view 340 × 272 mm², matrix size 256 × 144, slice thickness 8 mm, voxel size 1.3 × 1.9 × 8.0 mm³, TR/TE 2.6/1.1 ms, parallel imaging factor of 2. The matrix size was decreased to 192 × 128 for heart rates > 90 (approximate voxel size 1.8 × 2.1 × 8 mm³). T2 mapping was performed using a breath-held, ECG-triggered, bSSFP sequence with motion correction. Typical imaging parameters were as follows: Adiabatic T2 preparation with 35 degree flip angle, field of view 340 × 272 mm², matrix size 192 × 144, slice thickness 8 mm, voxel size 1.8 × 1.9 × 8.0 mm³, TR/TE 2.5/1.1 ms, parallel imaging factor of 2.

CMR post-processing
CMR post-processing was performed blinded to clinical data. Ventricular volumes and function were calculated using QMass (MedisSuite 2.1, Medis, Leiden, The Netherlands). The presence or absence of LGE, as well as location using the standard 17-segment model [10], was qualitatively assessed by two cardiologists, both with over 10 years of CMR experience. If there was disagreement, a third cardiologist assessed for LGE. Areas of LGE determined not to be due to myocardial infarction were included in the analysis, as these were felt to be the most focal areas in a continuum of diffuse extracellular matrix expansion [11]. LGE quantification was performed using the full-width half-maximum method, as this has previously been shown to have a stronger correlation with adverse outcomes in myocarditis [12]. Isolated inferior RV insertional LGE was not deemed to be pathologic as this is a common finding among athletes and was therefore not included in LGE quantification [4, 7].

T1 maps were obtained prior to and after contrast administration as previously described [13]. Extracellular volume fraction (ECV) maps were created using Qmaps (Medis) from native T1 and post-contrast T1 maps as well as a hematocrit obtained at the time of the scan. Regions of Interest (ROIs) were manually drawn on T1, T2, and ECV maps within the LV mesocardium, carefully avoiding partial volume averaging with blood-pool or epicardial fat and artifact. As per our lab protocol, ROIs were placed in the septum and free wall of the basal and mid short-axis slices, as well as in areas with focal abnormalities identified after visual inspection. Acute myocarditis was diagnosed according to the modified Lake Louise criteria [14].

Statistical analysis
Categorical variables were compared using the Pearson's chi-squared test or Fisher exact test and reported as frequency and percentage. Continuous variables were compared using the Wilcoxon rank sum and presented as median and interquartile range (IQR). Statistical analysis was performed using STATA (version 15 m Stata Corporation, College Station, Texas, USA). All tests were 2-sided and a p-value < 0.05 was considered significant. The study was approved by the institutional review board at Vanderbilt University Medical Center which waived informed consent.

Results
Fifty cases and 50 healthy soldier controls met inclusion criteria with a median age of 27 years and 25 years, respectively (Table 1); 98% were male. The majority of cases (98%) and controls (98%) were active duty personnel. Eighty-six percent of soldier cases experienced acute cardiovascular symptoms with COVID-19 and 94% experienced cardiovascular symptoms during the late convalescent phase; 84% had dyspnea on exertion, 71% reported chest pain, and 18% had palpitations. The most common indication for CMR among soldier controls was an abnormal screening ECG or transthoracic echocardiogram (N=24) followed by chest pain (N=21), palpitations (N=6), syncope (N=5), or another indication (N=5).

Initial COVID-19 severity was mild in 4%, moderate with cardiovascular symptoms in 86%, and severe with
hospitalization in 10% (N = 5), 2 of whom required ICU care. None of the hospitalized soldier cases (N = 5, 10%) had an abnormal CMR. Troponin I was normal in 96% at a median 33 days post-SARS-CoV-2 detection. Two soldier cases (4%) had troponin I > 99% of the upper reference limit of normal on multiple samples, neither of whom had an abnormal CMR. Four soldier cases (8%) had an abnormal baseline ECG, none of whom had an abnormal CMR.

The median time from SARS-CoV-2 infection to CMR in cases was 71 days (IQR 47–103; range 22–197). There were no differences in baseline demographics, laboratory findings, CMR LV parameters, or CMR parametric mapping (T1, T2 or ECV) findings between cases and controls (Table 2). Soldier cases had reduced RVEF compared to controls (51.0% vs. 53.2%, p=0.012). While soldier cases had a trend towards increased RV volumes, this did not reach statistical significance (Table 2). Soldier cases had more myocarditis-type LGE than controls (8% vs. 0%, p=0.03; Table 2).

Eleven (22%) of soldier cases had myocardial LGE. Four cases (8%) were diagnosed with myocarditis (1 acute

### Table 1 Demographics and cardiovascular magnetic resonance (CMR) data among COVID-19+ soldiers (soldier cases) compared to healthy soldier controls

|                                   | Soldier cases (N = 50) | Soldier healthy controls (N = 50) | P value |
|-----------------------------------|------------------------|----------------------------------|---------|
| Age, median (IQR), years          | 26.5 (23, 31)          | 25 (23, 33)                      | 0.82    |
| Height, cm                        | 178 (175, 183)         | 177 (173, 185)                   | 0.95    |
| Weight, kg                        | 87 (78, 99)            | 86 (75, 98)                      | 0.83    |
| Body surface area, kg/m²          | 2.1 (2.0, 2.2)         | 2.1 (1.9, 2.2)                   | 0.80    |
| Gender, male                      | 49 (98%)               | 49 (98%)                         | 0.75    |
| Active duty                       | 49 (98%)               | 49 (98%)                         | 1.00    |
| Creatinine, mg/dL                 | 0.9 (0.9, 1.0)         | 1.1 (1.0, 1.2)                   | n/a     |
| Hematocrit, %                     | 44 (43, 46)            | 42 (41, 44)                      | n/a     |
| Acute cardiovascular symptoms, N, %| 42 (86%)               | n/a                              | n/a     |
| (*Convalescent) CV symptoms       | 46 (94%)               | n/a                              | n/a     |
| Dyspnea on exertion               | 41 (84%)               | 3 (6%)                           | <0.001  |
| Chest pain                        | 35 (71%)               | 21 (42%)                         | 0.005   |
| Palpitations                      | 9 (18%)                | 6 (12%)                          | 0.401   |
| COVID-19 severity N (%)           | 2 (4%)                 | n/a                              | n/a     |
| Mild (no CV symptoms)             | 42 (86%)               | n/a                              | n/a     |
| Moderate (CV symptoms)            | 42 (86%)               | n/a                              | n/a     |
| Severe (hospitalized)             | 3 (6%)                 | n/a                              | n/a     |
| Severe (ICU)                      | 2 (4%)                 | n/a                              | n/a     |
| CV PASC Survey completion, N, %    | 19 (39%)               | n/a                              | n/a     |
| Median time to survey (days)      | 91                     | n/a                              | n/a     |
| Ongoing CV symptoms               | 6 (32%)                | n/a                              | n/a     |
| Laboratory                        |                        |                                  |         |
| Troponin I > 99%                   | 2 (4%)                 | 0 (0%)                           | n/a     |
| Abnormal ECG                       | 4 (8.5%)               | 9 (28%)                          | 0.05    |
| Hematocrit                         | 44 (43, 45)            | 42 (41, 43)                      | 0.06    |

*CV cardiovascular, ECG electrocardiogram, ICU intensive care unit, n/a not applicable

*Convalescent CV symptoms for soldier cases, compared to any CV symptoms for controls
myocarditis, 3 with healing myocarditis-pattern LGE), one of whom (2%) had concurrent pericarditis (Fig. 1). One soldier (2%) was diagnosed with Takotsubo cardiomyopathy after selective coronary angiography confirmed the absence of obstructive coronary artery disease (Fig. 2), and one soldier (2%) had new biventricular systolic dysfunction without myocarditis. All of the soldiers with myocarditis had preserved biventricular

Table 2 Imaging data among COVID-19+ soldiers (soldier cases) compared to soldier controls

|                     | Soldier cases (N = 50) | Soldier healthy controls (N = 50) | P value |
|---------------------|-----------------------|----------------------------------|---------|
| LVEF, median (IQR), % | 59.5 (56.9, 63.0)     | 57.8 (55.7, 61.3)                | 0.24    |
| LVEDV, mL           | 178.0 (162.2, 201.4)  | 188.5 (165.2, 211.6)             | 0.12    |
| LVEDVI, mL/m²       | 84.9 (79.8, 94.5)     | 91.2 (82.6, 103.0)               | 0.059   |
| LVESV, mL           | 70.6 (61.2, 85.6)     | 78.8 (61.9, 89.2)                | 0.17    |
| LVESVI, mL/m²       | 34.6 (30.1, 39.4)     | 39.2 (31.8, 44.6)                | 0.025   |
| LV mass, g          | 134.3 (116.1, 146.1)  | 122.9 (110.4, 139.5)             | 0.06    |
| LV mass index, g/m² | 64.6 (58.4, 69.1)     | 59.6 (55.6, 65.5)                | 0.023   |
| RVEF, %             | 51.0 (48.5, 54.0)     | 53.2 (50.8, 58.7)                | 0.012   |
| RVEDV, mL           | 200.8 (178.0, 224.8)  | 183.2 (168.9, 237.0)             | 0.33    |
| RVESV, mL/m²        | 98.0 (86.9, 109.5)    | 93.8 (80.6, 109.5)               | 0.35    |
| RVESVI, mL/m²       | 100.5 (85.7, 116.1)   | 85.3 (70.7, 110.6)               | 0.10    |
| T₁ median (IQR), ms | 47.8 (42.6, 55.2)     | 43.1 (34.6, 51.1)                | 0.052   |
| Mid septum          | 982.2 (953.6, 991.7)  | 982.8 (966.0, 998.6)             | 0.22    |
| Mid lateral         | 970.7 (952.9, 985.1)  | 964.5 (948.3, 987.0)             | 0.42    |
| Mid global          | 971.5 (953.4, 985.8)  | 972.5 (961.7, 987.6)             | 0.44    |
| T₂ median (IQR), ms | 45.3 (43.8, 46.7)     | 44.8 (43.9, 46.3)                | 0.71    |
| Mid septum          | 45.1 (43.7, 45.9)     | 45.4 (44.0, 46.7)                | 0.72    |
| Mid lateral         | 45.3 (44.3, 46.3)     | 45.4 (44.4, 46.3)                | 0.69    |
| ECV (global), %     | 23.6 (22.1, 25.2)     | 22.7 (21.9, 23.1)                | 0.38    |
| Mid septum          | 22.1 (20.5, 22.9)     | 20.8 (20.7, 22.4)                | 0.58    |
| Mid septum          | 23.0 (21.3, 24.1)     | 22.3 (22.0, 24.3)                | 0.97    |
| LGE                 | Any, N (%)            | Any, N (%)                       | n/a     |
| Inferior RV septal insertion | 8 (16%) | 8 (23.5%)               | 0.09    |
| Subepicardial inferolateral | 4 (8%) | 0 (0%)                 | 0.03    |
| Diagnosis           | Myocarditis           | 4 (8%)                           | n/a     |
| Takotsubo cardiomyopathy | 1 (2%) | 0 (0%)                 | n/a     |

ECV extracellular volume, LGE late gadolinium enhancement, LV left ventricle, LVEDV left ventricular end-diastolic volume, LVEDVI left ventricular end-diastolic volume index, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, LVESVI left ventricular end-systolic volume index, RVESV right ventricular end-diastolic volume, RVESVI right ventricular end-systolic volume index, RVEF right ventricular ejection fraction, n/a not applicable

a N = 11
b N = 48
c N = 47
d N = 13
e N = 5
f N = 46
g N = 4
h N = 49
i N = 34
systolic function. The mean quantified pathologic LGE was 6.2% of the myocardial mass, using the full-width half-maximum method. Isolated inferior RV septal insertion LGE was present in 8 cases and 8/34 controls who received contrast (16% vs. 24%, p = 0.09).

### Table 3

Soldier cases compared by presence versus absence of post-acute sequelae of SARS-CoV-2 infection (CV PASC)

|                      | CV PASC (N = 7) | No PASC (N = 12) | P value |
|----------------------|----------------|-----------------|---------|
| LVEF, median (IQR), %| 57.8 (57.1, 63.1) | 57.9 (54.7, 61.5) | 0.45    |
| LVEDV, mL           | 168.1 (164.3, 207.7) | 184.6 (168.1, 206.3) | 0.61    |
| LVEDVI, mL/m²       | 84.3 (82.5, 96.0) | 84.3 (81.9, 95.2) | 0.61    |
| LVESV, mL           | 69.0 (64.3, 81.1) | 74.6 (65.5, 92.1) | 0.35    |
| LV mass, g          | 34.8 (32.2, 38.3) | 36.4 (32.4, 40.5) | 0.53    |
| LV mass index, g/m² | 136.4 (127.3, 158.2) | 130.5 (126.2, 140.5) | 0.47    |
| LV mass index, g/m² | 64.8 (62.6, 74.8) | 62.5 (58.7, 66.7) | 0.16    |
| RVEF, %             | 50.6 (48.3, 52.0) | 50.5 (46.9, 53.2) | 0.87    |
| RVEDV mL            | 221.0 (192.2, 276.3) | 208.6 (188.3, 226.0) | 0.40    |
| RVESV mL/m²         | 107.9 (94.9, 129.3) | 99.6 (88.0, 105.8) | 0.24    |
| RVESVI, mL/m²       | 110.3 (95.1, 135.7) | 105.3 (90.3, 114.4) | 0.55    |
| T₁, median (IQR), ms| 986.4 (958.5, 1007.7) | 985.6 (964.0, 994.1) | 0.74    |
| T₁, median (IQR), ms| 970.2 (962.2, 983.7) | 973.1 (944.6, 1001.0) | 0.80    |
| T₁, median (IQR), ms| 972.1 (956.0, 1003.6) | 978.5 (953.9, 996.3) | 0.99    |
| Mid septum          | 45.7 (45.0, 47.4) | 44.7 (43.8, 45.7) | 0.10    |
| Mid lateral         | 45.5 (44.6, 45.6) | 45.6 (43.8, 46.1) | 0.62    |
| Mid global          | 45.7 (44.8, 47.5) | 45.3 (44.1, 46.1) | 0.10    |
| ECV (global), %     | 25.4 (24.1, 26.1) | 23.4 (22.3, 25.3) | 0.12    |
| Mid septum          | 23.9 (22.0, 25.7) | 23.0 (21.3, 23.4) | 0.36    |
| Mid lateral         | 23.0 (22.5, 24.2) | 22.1 (20.5, 22.5) | 0.06    |
| Mid global          | 23.9 (22.0, 25.7) | 23.0 (21.3, 23.4) | 0.36    |
| LGE                  | 3 (42.9%) | 1 (9.1%) | 0.25    |
| Inferior RV septal insertion | 1 (14.3%) | 1 (9.1%) | 0.99    |
| Subepicardial inferolateral | 2 (28.6%) | 0 (0%) | 0.14    |
| Diagnosis            | 2 (28.6%) | 0 (0%) | 0.14    |

* N = 6

### Table 4

Follow-up CMR in soldier cases with COVID-19 myocarditis

| Case | CMR1 (days since diagnosis) | CMR1%LGE | CMR2 (days since diagnosis) | CMR2%LGE | CMR3 (days since diagnosis) | CMR3%LGE |
|------|-----------------------------|----------|-----------------------------|----------|-----------------------------|----------|
| 1    | 33                          | 8.8      | 82                          | 2.8      | 119                         | 0        |
| 2    | 124                         | 3.5      | 271                         | 3.5      |                             |          |
| 3    | 38                          | 5.1      | 122                         | 5.1      | 213                         | 5.1%     |
| 4    | 97                          | 7.4      | 192                         | 2.1      | 245                         | 0        |
Fig. 1 1st row (A–D): Phase sensitive inversion recovery (PSIR) images in the short-axis plane demonstrating focal areas of late gadolinium enhancement (LGE) in a subepicardial distribution typical of myocarditis (yellow arrowheads); 2nd row (E–H): long-axis PSIR images demonstrating focal areas of LGE in a pattern consistent with myocarditis (yellow arrowheads); 3rd row (I–L): native myocardial T1 map, I: 975 ms global base, J: 995 ms global base, K: 1010 ms global base, L: 980 ms global base; 4th row (M–P): myocardial T2 map, M: 43.0 ms global base, N: 45.5 ms global base, O: 46.5 ms global base, region of interest (basal inferolateral wall): 52.0 ms, P: 42.7 ms global base.

Fig. 2 Soldier case with Takotsubo cardiomyopathy. A Phase sensitive inversion recovery (PSIR) short-axis images revealing no myocardial or pericardial late gadolinium enhancement (LGE), B, C Normal coronary arteries on angiography, and D Basal hyperkinesis with mild apical ballooning on left ventriculogram.
asymptomatic acute-COVID or with resolution of acute cardiovascular symptoms went on to develop CV PASC. Two (29%) of soldier cases with CV PASC had a pathological clinical diagnosis (myocarditis) on CMR (Table 3).

There were no significant volumetric or parametric differences between soldier cases with or without CV PASC, but soldiers with CV PASC were more likely to have myocarditis-pattern LGE than those without CV PASC (Table 3).

**Follow-up CMR**
All 4 soldier cases with myocarditis have undergone follow-up CMR. Case 1 had inferolateral LGE and normal T2 time on the initial CMR (33 days post-COVID-19 diagnosis) and demonstrated complete resolution of LGE (reduction of LGE burden from 8.8 to 2.8% at 82 days post-infection and complete resolution 119 days post-infection; Table 4). Case 2 had myocarditis-type LGE (3.5% burden) on the initial CMR 124 days post-infection, which remained unchanged on a follow-up CMR 271 days post-infection. Case 3 had persistent LGE (5.1% burden) and ongoing mild T2 elevation (51 ms) on repeat CMRs 122 days and 213 days following infection. Case 4 had basal-to-mid-LV inferoseptal and inferolateral myocarditis-type LGE (7.4% burden) on the initial CMR 97 days post-infection, which decreased to 2.1% on CMR 192 days post-infection, and completely resolved by CMR 245 days post-infection (Table 4).

**Discussion**
This study suggests that the prevalence of myocarditis-type LGE (8%) is considerable in soldiers with cardiovascular symptoms in the late convalescent phase of COVID-19. The focus on late convalescent CMR is critical as the pandemic transitions from management of acute infections to assessment and treatment of previously infected patients with ongoing symptoms. This study helps inform the yield of CMR among this increasingly larger group of individuals post-COVID-19 with ongoing cardiac symptoms. To our knowledge, this is the first study to report the CMR findings in soldiers after SARS-CoV-2.

Soldier cases were noted to have a reduced RVEF compared to controls, as has been reported in other publications [2, 15]. These findings are intriguing and merit consideration that COVID-19 may preferentially affect the RV either directly, or indirectly from lingering effects of COVID-19 related lung disease [16].

Athletic remodeling with increased chamber volumes and low-normal biventricular systolic function was similarly present in cases and controls. Punctate inferior RV septal insertional LGE was also common in both cases and controls. This finding is consistent with our prior report in collegiate athletes and is likely due to athletic remodeling, not myocarditis secondary to COVID-19, and again emphasizes the critical importance of an athletic control group [4, 7].

CV PASC was common among soldiers (37%) and was exclusively reported in soldiers with similar symptoms during the acute and early convalescent phases of illness. Soldiers with CV PASC trended towards having more myocarditis (28.6% vs. 0%, p = 0.14, Table 3). Other more subtle differences between these groups may not have reached statistical significance due to the small number of subjects in this sub-analysis. Follow-up CMR among myocarditis cases showed two patterns: recovery with gradual LGE resolution, and persistence with one soldier having ongoing active myocarditis with T2 elevation more than 7 months after COVID diagnosis.

**Limitations**
Because CMR was performed at a median time of 71 days after infection, milder cases of myocarditis may have been missed if edema and LGE resolved quickly. The sensitivity of troponin I as a biomarker for COVID-19 myocarditis may be limited due to the necessary quarantine period and the delayed acquisition of these samples (median 33 days post-SARS-CoV-2 in soldier cases). Controls were not prospectively obtained, but rather derived retrospectively from a convenience soldier sample with clinical indications for CMR, and thus may have subtle abnormalities that would not be present in an asymptomatic, prospectively enrolled control group. However, controls were matched by age, sex, and athletic phenotype to account for known athletic cardiac remodeling and were only included if they had undergone CMR at a date prior to the first case of SARS-CoV-2 in our region, thereby eliminating concern for undiagnosed prior COVID-19. Although the survey response rate was not unreasonable (39%), smaller numbers could impact our results.

**Conclusions**
Cardiovascular pathology was diagnosed in 12% of soldiers after recovery from SARS-CoV-2, with myocarditis found in 8%. Compared to matched soldier controls, RVEF is lower in soldiers after recovery from COVID-19. CV PASC occurred in over one-third of soldiers surveyed but did not occur in any soldiers with asymptomatic acute SARS-CoV-2 infection. Ongoing investigations into the cardiovascular sequelae of COVID-19 are crucial in tailoring data-driven return-to-service recommendations for our soldiers.

**Abbreviations**
ACC: American College of Cardiology; bSSFP: Balanced steady state free precession; CMR: Cardiovascular magnetic resonance; COVID-19: Coronavirus disease-2019; CV PASC: Post-acute sequelae of SARS-CoV-2 infection with
cardiovascular symptoms; ECG: Electrocardiogram; ECV: Extracellular volume fraction; IQR: Interquartile range; LGE: Late gadolinium enhancement; L.V: Left ventricle/left ventricular; LVEDV: Left ventricular end-diastolic volume; LVEDVI: Left ventricular end-diastolic volume index; LVESV: Left ventricular end-systolic volume; LVESVI: Left ventricular end-systolic volume index; MOLLI: Modified look-locker inversion recovery; PASC: Post-acute sequelae of SARS-CoV-2 infection; PSIR: Phase sensitive inverse; RV: Right ventricle/right ventricular; RVEDV: Right ventricular end-diastolic volume; RVEDVI: Right ventricular end-diastolic volume index; RVEF: Right ventricular ejection fraction; RVESV: Right ventricular end-systolic volume; RVESVI: Right ventricular end-systolic volume index; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SCD: Sudden cardiac death.

Acknowledgements
The authors would like to acknowledge our exceptional CMR technologists (Shannon Bozeman, Dana Fuhs, Matt Herscher, and Miranda Tweedy) for obtaining phenomenal images and working overtime for the screening of these athletes.

Authors’ contributions
DC, SH, and JS designed the study and drafted the manuscript. DC, KC, JD, DL, DD, AP, and JW acquired data. KGD supported standardized CMR measurements and analysis. DC and JS supported statistical analysis. DC, SH, and JS substantially contributed to the manuscript and revised it critically for important intellectual content. SH and JS contributed equally as senior authors. All authors read and approved the final manuscript.

Funding
Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number T32HL007411. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The publication described was supported by CTSA Award No. UL1 TR002243 from the National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The need for informed consent was waived by the institutional review board (IRB) of Vanderbilt University Medical Center (VUMC) for this retrospective study. The study protocol was approved by the VUMC IRB (No. 201657) and the study has been performed in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
All authors declare no competing interests.

Author details
1Division of Cardiovascular Medicine, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. 2Vanderbilt University Medical Center, 2220 Pierce Avenue, 383 Preston Research Building, Nashville, TN 37237, USA.

Received: 29 March 2021 Accepted: 26 July 2021 Published online: 07 October 2021

References
1. Eckert RE, Scoville SL, Campbell CL, Shry EA, Sajduhar KC, Potter RN, et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med. 2004;141(11):829–34.
2. Puntmann VO, Gaters ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–73.
3. Rappal SJ, Tong MS, Borchers J, Zareba KM, Obarski TP, Simonetti OP, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021;6(11):116–8.
4. Clark DE, Parkh A, Dendy JM, Diamond AB, George-Durrett K, Fish FA, et al. COVID-19 myocardial pathology evaluation in athletes with cardiac magnetic resonance (COMPETE-CMR). Circulation. 2021;143(6):609–12.
5. Starekova J, Bluemke DA, Bradham WS, Eichkort LR, Grist TM, Kusmirek JE, et al. Evaluation for myocarditis in competitive student athletes recovering from coronavirus disease 2019 with cardiac magnetic resonance imaging. JAMA Cardiol. 2021;2(10):609–12.
6. Kim JH, Levine BD, Phelan D, Emery MS, Martinez MW, Chung EH, et al. QT dispersion in young competitive athletes recovering from COVID-19. JAMA Cardiol. 2020;5(11):1190–5.
7. Domenech-Ximenes B, Sanz-de la Garza M, Prat-González S, Sepulveda-Martínez A, Crippa F, Duran-Fernandez K, et al. Prevalence and pattern of cardiovascular magnetic resonance late gadolinium enhancement in highly trained endurance athletes. J Cardiovasc Magn Reson. 2020;22(1):62.
8. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.
9. Gati S, Sharma S, Pennell D. The role of cardiovascular magnetic resonance imaging in the assessment of highly trained athletes. JACC Cardiovasc Imaging. 2018;11(2 Pt 1):247–59.
10. Cercarera MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. J Nucl Cardiol. 2002;9(6):240–5.
11. Dabir D, Child N, Kalra A, Rogers T, Gbeker R, Jabbour A, et al. Reference values for healthy human myocardium using a T1 mapping methodology: results from the International T1 Multicenter cardiovascular magnetic resonance study. J Cardiovasc Magn Reson. 2014;16:69.
12. Grani C, Eichhorn C, Breie L, Kaneko K, Murthy VL, Agarwal U, et al. Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis. J Cardiovasc Magn Reson. 2019;21(11):14.
13. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Killman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2*, and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):75.
14. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonschismic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158–76.
15. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalasaran KV, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J. 2021;42(19):1866–78.
16. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683.